Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection

Cancer

Volumn 115, Issue 6, 2009, Pages 1310-1317

  Svatek, Robert S ^a   Spiess, Philippe E ^b   Sundi, Debasish ^a   Tu, Shi Ming ^a   Tannir, Nizar M ^a   Brown, Gordon A ^a   Kamat, Ashish M ^a   Wood, Christopher G ^a   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Outcome; Postchemotherapy; Predictors; Retroperitoneal lymph node dissection; Teratoma

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; TUMOR MARKER; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FOLLOW UP; GERM CELL TUMOR; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NONSEMINOMATOUS GERM CELL TUMOR; PRIORITY JOURNAL; PROBABILITY; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK ASSESSMENT; TERATOMA; TESTIS CANCER; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

ADULT; DISEASE PROGRESSION; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; PROGNOSIS; RECURRENCE; RETROPERITONEAL NEOPLASMS; TERATOMA; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 63449114244     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24145     Document Type: Article

References (24)

1. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from 6 study groups. J Clin Oncol. 1995;13:1177-1187.
2. Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer. 1982;50:1629-1635.
3. Loehrer PJ Sr, Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135:1183-1189.
4. Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82:1343-1351.
5. Spiess PE, Kassouf W, Brown GA, et al. Surgical management of growing teratoma syndrome: the M. D. Anderson Cancer Center experience. J Urol. 2007;177:1330-1334; discussion 1334.
6. Debono DJ, Heilman DK, Einhorn LH, et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15:1455-1464.
7. Spiess PE, Tannir NM, Brown GA, et al. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007;70:1173-1178.
8. Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994;74:1329-1334.
9. Davey DD, Ulbright TM, Loehrer PJ, et al. The significance of atypia within teratomatous metastases after chemotherapy for malignant germ cell tumors. Cancer. 1987;59:533-539.
10. Donohue JP, Roth LM, Zachary JM, et al. Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol. 1982;127: 1111-1114.
11. Fossa SD, Qvist H, Stenwig AE, et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992;10:569-573.
12. Sella A, el Naggar A, Ro JY, et al. Evidence of malignant features in histologically mature teratoma. J Urol. 1991; 146:1025-1028.
13. Tait D, Peckham MJ, Hendry WF, et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984;50:601-609.
14. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25:1033-1037.
15. [Noauthors listed] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594-603.
16. Logothetis CJ, Samuels ML, Selig D, et al. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol. 1985;3:326-335.
17. Fizazi K, Do KA, Wang X, et al. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002;13:125-134.
18. Fizazi K, Prow DM, Do KA, et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002; 86:1555-1560.
19. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23:2781-2788.
20. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8:1683-1694.
21. Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164:381-384.
22. Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemo-therapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23:6149-6156.
23. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324-329.
24. Donohue JP, Leviovitch I, Foster RS, et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65-71.